Singapore — Quadria Capital, one of Asia’s largest healthcare-focused private equity firms, has closed its third fund with $1.07 billion in commitments, surpassing its initial $800 million target despite a challenging capital-raising environment.
The oversubscribed Fund III includes $954 million in primary capital and $114 million in committed co-investment funds, with an additional $300 million of co-investment capacity expected during the investment period.
This brings the total capital pool to as much as $1.3 billion upon full deployment.
The fund, roughly 60% larger than its 2020 predecessor, positions Quadria as the largest dedicated healthcare PE firm in South and Southeast Asia.
The firm plans to back 10 market-leading companies, with both majority and significant minority stakes, and scale them through strategic co-investments.
“Fund III’s close, amid one of the most demanding fundraising climates in recent memory, is a powerful validation of our strategy and our mission” said Abrar Mir, Co-Founder and Managing Partner, Quadria Capital. “It reflects deep global investor conviction in the transformational opportunity in Asian Healthcare, where social impact and financial performance go hand in hand”.
Quadria attracted capital from a mix of global sovereign wealth funds, asset managers, and strategic corporates across North America, Europe, and the Gulf, alongside rising participation from institutional and family office investors in Asia.
Existing backers increased their commitments by an average of 80%, underscoring confidence in Quadria’s impact-driven investment thesis.
Nearly 40% of the fund is already deployed in companies including Aragen Life Sciences, NephroPlus, and Maxivision, with two Southeast Asian deals nearing close.
With Asia poised to drive 40% of global healthcare growth by 2030, Quadria sees growing investor appetite in areas like specialty hospitals, diagnostics, medtech, and pharmaceutical manufacturing, particularly in India and Southeast Asia.
The close affirms Quadria’s strategy of combining financial returns with scalable healthcare solutions for underserved populations, aligning with broader investor interest in resilient, high-impact sectors across emerging Asia.
Business News Asia